1. Introduction {#sec1}
===============

Obesity is associated with dysregulated body-weight homeostasis, and is the primary risk factor for the development of type 2 diabetes, hypertension, and cardiovascular disease [@bib1]. Obesity continues to reach epidemic proportions in North America, elevating morbidity and mortality rates, while providing a cumbersome economic burden. These trends highlight a need for further development in the field of metabolic physiology, an area that has been advanced by the identification of endogenous compounds regulating food intake and energy expenditure.

One such compound is α-Klotho, an anti-aging protein secreted by the kidney and the brain to exhibit multiple hormonal effects [@bib2] including: maintenance of vitamin D and calcium homeostasis \[[@bib3], [@bib4]\], modulation of cell senescence [@bib5], and production of reactive oxygen species buffering enzymes [@bib6]. α-Klotho may also be associated with whole-body energy metabolism, evidenced by impaired circulating α-Klotho concentrations in obese and diabetic human patients \[[@bib7], [@bib8]\]. α-Klotho overexpression in db/db mice attenuates hyperglycemia and hyperphagia [@bib6], and can even extend the lifespan in healthy mice [@bib9]. Furthermore, genetic deletion of α-Klotho suppresses uncoupling protein 1 gene expression, decreases temperature in brown adipose tissue, and trends to increase food intake relative to body weight [@bib10].

Despite this encouraging evidence, the specific role of α-Klotho in regulation of energy homeostasis is complicated and not completely understood. For example, similar to overexpression models, genetic knockdown of α-Klotho in mice also increases insulin sensitivity [@bib11]. α-Klotho provides negative feedback to insulin and IGF-1 signaling to modulate cell proliferation and improve tolerance to oxidative stress \[[@bib12], [@bib13], [@bib14], [@bib15]\], but also facilitates insulin release via transient receptor protein channel modification and improved calcium flux [@bib16]. Additionally, α-Klotho deletion promotes extreme leanness, but ultimately results in premature death in mouse models \[[@bib9], [@bib17]\]. These mice experience drastically impaired development, manifesting as osteoporosis, reduced adiposity, and atrophied organs \[[@bib10], [@bib17]\].

Overall, α-Klotho\'s exact involvement in the pathophysiology, or even treatment, of obesity is not understood completely. Models genetically altering α-Klotho levels provide encouraging evidence indicating a prominent role of α-Klotho in whole-body energy metabolism, however, these models have conflicting results and lack insight into α-Klotho\'s tissue-specific mechanisms of action. Consequently, this study aimed to investigate the effects of intraperitoneal α-Klotho administration on the physiology of metabolically active organs. Furthermore, this model provides a direct translational look into the therapeutic potential of α-Klotho to treat obesity and metabolic disease.

2. Materials and methods {#sec2}
========================

2.1. Materials {#sec2.1}
--------------

### 2.1.1. Animals {#sec2.1.1}

All aspects of animal care and experimentation were conducted in accordance with the National Institutes Health "Guide for the Care and Use of Laboratory Animals" (NIH Publication No. 85-23, revised 1996) and approved by the Institutional Animal Care and Use Committees of East Carolina Diabetes and Obesity Institute. 24 C57BL6 male mice (JAX Stock No: 00664) from Jackson lab (The Jackson Laboratory, Bar Harbor, Maine) were fed a high-fat diet with a kilocalorie composition of 58%, 25%, and 17% fat, carbohydrate, and protein respectively for 8 weeks (D12331, Research Diets, New Brunswick, NJ). Mice were housed under controlled temperatures at 22--24 °C and a 12 h light/12 h dark cycle.

### 2.1.2. Reagent {#sec2.1.2}

The recombinant mouse α-Klotho protein (aa 35-982) was obtained from R & D Systems (Minneapolis, MN).

2.2. Methods {#sec2.2}
------------

### 2.2.1. Treatment protocol {#sec2.2.1}

Six-week-old, male, C57BL/6 mice were fed a high-fat diet (HFD) for 8 weeks. Mice were then intraperitoneally treated with α-Klotho protein (0.02 mg/kg) or saline every 48 h. for 5 weeks. At week 18 (4 weeks into α-Klotho or saline treatment) indirect calorimetry was performed and at week 19 mice were euthanized for further analysis of metabolically active tissues.

### 2.2.2. Body composition and food intake {#sec2.2.2}

Body weight and food intake were recorded weekly. Total fat and lean mass were assessed using EchoMRI (Echo Medical Systems, Houston, TX). Epididymal white adipose tissue (eWAT) was harvested. Mice were individually housed for 1 week, followed by weekly measurement of food intake. Food intake data were combined, averaged, and analyzed by unpaired Student\'s t tests. To maximize accuracy of food intake measurements, a white bedding paper under the food bowl was used to collect residual food crumbs and all uneaten food was measured. This amount was subtracted from the total food given to calculate total amount of food intake.

### 2.2.3. Energy expenditure {#sec2.2.3}

Energy expenditure was measured by assessing oxygen consumption with indirect calorimetry. Individually housed male mice on a HFD and 18 weeks of age (4 weeks into α-Klotho or saline treatment) were studied, using the Comprehensive Lab Animal Monitoring System (CLAMS, Columbus Instruments, Columbus, OH). Mice were acclimated in the CLAMS chambers for 72 hours before data collection. Mice had free access to food and water for the duration of the studies. Values from individual time points were totaled and analyzed by unpaired Student\'s t tests comparing two groups. All data were normalized for body weight.

### 2.2.4. Histopathology {#sec2.2.4}

At the end of the experiment, livers were frozen in liquid hydrogen and then cryostat-sectioned at a thickness of 5 μm onto poly-l-lysine slides for lipid deposition analysis by Oil Red O staining. eWAT was frozen in liquid hydrogen and then cryostat-sectioned at a thickness of 20 μm onto poly-l-lysine slides for adipocyte size measurement. The red areas and adipocyte size were quantified by Image J [@bib18].

### 2.2.5. Quantitative real-time PCR {#sec2.2.5}

Total RNA from liver or eWAT was extracted using TRIzol reagent (Invitrogen) and subjected to quantitative real-time PCR as described previously [@bib19]. Gene-specific primer sequences are listed in Supplemental Table 1. Relative gene expressions were calculated with the delta-delta CT method with 18s ribosomal RNA normalization, using ViiA 7 system (Applied Biosystems).

### 2.2.6. Triglyceride content in blood, adipose tissue and liver {#sec2.2.6}

To quantify changes in triglyceride concentrations in blood, adipose tissue, and liver, a Triglyceride Colorimetric Assay Kit (Cat. \# 10010303, Cayman Chemical, Ann Arbor MI) was used according to the manufacturer\'s instruction. Each biological replicate was analyzed in duplicate.

### 2.2.7. Statistical analysis {#sec2.2.7}

Data are expressed as the mean ± SEM. Unpaired Student\'s t tests were used throughout this study to compare two distinct groups using GraphPad Prism 5 software (San Diego, CA). P \< 0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. α-Klotho improves body composition in obese mice despite no changes in food intake and body weight {#sec3.1}
-------------------------------------------------------------------------------------------------------

There were no differences in food intake and body weight between α-Klotho and saline groups throughout the experiment ([Fig. 1](#fig1){ref-type="fig"}a and b). Despite no changes in body weight, at the end of the experiment fat mass was decreased (Saline: 38.3% ± 1.0% versus α-Klotho: 34.0% ± 0.6%) ([Fig. 1](#fig1){ref-type="fig"}c) and lean mass was increased (Saline: 54.8% ± 1.2% versus α-Klotho: 60.0% ± 0.7%) ([Fig. 1](#fig1){ref-type="fig"}d) in α-Klotho treated mice. There were no differences in fed glucose levels, liver glycogen contents, and serum triglyceride concentrations between groups ([Fig. 1](#fig1){ref-type="fig"}e, f, g).Fig. 1α-Klotho decreases fat mass and increases lean mass without changing body weight or food intake. (a) Food intake, (b) Body weight, (c) Percent fat mass, (d) Percent lean mass, (e) Fed glucose levels, (f) Liver glycogen content, and (g) Serum triglyceride concentrations in α-Klotho treated and control mice. Bar graphs show Mean + SEM. n = 6--7 per group; \* indicates p \< 0.05 vs saline group.Fig. 1

3.2. α-Klotho increases energy expenditure in obese mice {#sec3.2}
--------------------------------------------------------

Energy expenditure was measured via indirect calorimetry using the Comprehensive Lab Animal Monitoring System over 7 days. Data were collected and analyzed from the last four days ([Fig. 2](#fig2){ref-type="fig"}a). α-Klotho-treated mice show significantly increased oxygen consumption during both day time (Saline: 2333 ± 113 ml/h/kg versus α-Klotho: 2628 ± 206 ml/h/kg) ([Fig. 2](#fig2){ref-type="fig"}b) and night time (Saline: 2726 ± 135 ml/h/kg versus α-Klotho: 3182 ± 263 ml/h/kg) ([Fig. 2](#fig2){ref-type="fig"}c).Fig. 2α-Klotho increases energy expenditure. (a) Oxygen consumption normalized to body weight, (b) Oxygen consumption during the day time, (c) and night time in α-Klotho treated and control mice. Bar graphs show Mean + SEM. n = 6--7 per group. \* indicates p \< 0.05 vs saline group.Fig. 2

3.3. α-Klotho reduces lipid accumulation in liver and white adipose tissue of obese mice {#sec3.3}
----------------------------------------------------------------------------------------

5-weeks administration of α-Klotho decreased lipid accumulation in the liver ([Fig. 3](#fig3){ref-type="fig"}a and b) (Frozen sections were stained by Oil Red O) and quantified by Image J ([Fig. 3](#fig3){ref-type="fig"}b). Triglyceride content was significantly decreased in α-Klotho treated mice compared with controls (Saline: 48.4 ± 3.3 mg/g versus α-Klotho: 37.7 ± 2.2 mg/g) ([Fig. 3](#fig3){ref-type="fig"}c). α-Klotho treatment also significantly decreased adipocyte size ([Fig. 3](#fig3){ref-type="fig"}d and e) and triglyceride content in epididymal white adipose tissue (Saline: 113.2 ± 25.2 mg/g versus α-Klotho: 75.7 ± 11.9 mg/g) ([Fig. 3](#fig3){ref-type="fig"}f).Fig. 3α-Klotho reduces liver lipid content and decreases adipocyte size. (a) Oil red o staining of liver, (b) Quantification of lipid area, and (c) liver triglyceride content, (d) Representative images of eWAT sections, (e) Quantification of adipocyte size, and (f) Epididymal white adipose tissue triglyceride content in α-Klotho treated and control mice. Bar graphs show Mean + SEM. n = 6--7 per group; The scale bars represent 50 μm \* indicates p \< 0.05 vs saline group.Fig. 3

3.4. α-Klotho modulates key gene expression related to lipid metabolism in liver and white adipose tissue {#sec3.4}
---------------------------------------------------------------------------------------------------------

To elucidate the molecular mechanism of α-Klotho\'s lipid lowering effects, we investigated expression of key genes related to lipid metabolism in liver and adipose tissue. Compared to saline-treated controls, α-Klotho treated mice had changes in liver gene expression associated with decreased lipogenesis, including reductions in ACC-α (0.75 fold) and ACC-β (0.60 fold) ([Fig. 4](#fig4){ref-type="fig"}a). Interestingly, ACOX1 (0.48 fold), PGC1α (0.6 fold), and PPARγ (0.65 fold), genes associated with fat oxidation, were also decreased in the livers of the α-Klotho group compared to controls ([Fig. 4](#fig4){ref-type="fig"}b). There were no changes in key gene expressions involved in hepatic glucose metabolism ([Fig. 4](#fig4){ref-type="fig"}c). In white adipose tissue, α-Klotho-treated mice showed significantly increased ACOX1 (2.2 fold) gene expression, while PPARα (0.63 fold) and PGC1α (0.7 fold) were decreased compared with controls ([Fig. 4](#fig4){ref-type="fig"}e). We also found strong trends toward decreased PPARγ and ACC-β and strong trends toward increased CPT1 and leptin in the adipose tissue of α-Klotho treated mice compared with controls ([Fig. 4](#fig4){ref-type="fig"}d, e and f). In brown adipose tissue, there was no alteration in key gene expression involved in thermogenesis ([Fig. 4](#fig4){ref-type="fig"}g).Fig. 4The effects of α-Klotho on gene expression in liver, eWAT, and BAT. (a) Hepatic levels of key gene expression involved in lipogenesis, (b) fat oxidation, (c) glucose metabolism. (d) eWAT levels of key gene expression involved in in lipogenesis, (e) fat oxidation, (f) secreting cytokines. (g) BAT levels of key gene expression involved in thermogenesis in α-Klotho treated and control mice. Bar graphs show Mean + SEM. n = 6--7 per group; \* indicates p \< 0.05 vs saline group.Fig. 4

4. Discussion {#sec4}
=============

The discovery of the "anti-aging protein" α-Klotho has generated research interest that has significantly advanced our current understanding of the aging process. Although α-Klotho was identified nearly 20 years ago, its specific function involving energy metabolism and related disease-states remains incompletely understood. We investigated the effects of intraperitoneal α-Klotho injection in the high fat diet induced obese (DIO) mouse model. We revealed a previously uncovered beneficial role of α-Klotho in the regulation of lipid accumulation in liver and adipose tissue. Overall, α-Klotho treatment resulted in elevated energy expenditure, decreased fat mass, and increased lean mass, despite no change in food intake or body weight. Further gene expression analysis began to elucidate the tissue-specific mechanisms underlying α-Klotho regulation of liver and adipose tissue metabolism.

In the livers of DIO mice treated with α-Klotho for 5 weeks, gene expression of the two isoforms of Acetyl-CoA carboxylase (ACC) was significantly decreased, indicating reduced inhibition of CPT-1, and increased fat oxidation. In the adipose tissue of α-Klotho-treated mice, ACOX1 and CPT1 gene expression was elevated, also suggesting increased fat oxidation. Interestingly, the thermogenic gene expression (UCP1) was not altered in α-Klotho treated mice, suggesting that browning of white adipose tissue is unlikely. α-Klotho also does not increase key gene expression associated with thermogenesis in brown adipose tissue. Moreover, decreased PPARγ and PGC1α mRNA in both these tissues indicates reduced lipogenesis. Notably, there were no changes in gene expressions that related to hepatic glucose metabolism, such as Phosphoglycerate Kinase 1 (PGK1), Glucose 6-phosphatase (G6Pase), Glucokinase (GK), liver type pyruvate kinase (L-PK), and Phosphoenolpyruvate carboxykinase (PEPCK). Supporting this data, no change in fed blood glucose levels were observed. However, no assays were performed during the fasted status. Due to this limitation, we cannot rule out the possibility that α-Klotho alters glucose levels or gene expression related to glucose metabolism during fasting conditions. Nonetheless, our data suggest distinct responses in lipid upon α-Klotho administration. The general trends in α-Klotho-induced changes in liver and adipose gene expression illustrate a shift in lipid metabolism favoring oxidation rather than storage. This metabolic shift would explain the reduced lipid accumulation observed in α-Klotho-treated DIO mice.

Interestingly, α-Klotho knock-out mice experience atrophy in many metabolic organs, including adipose tissue and liver \[[@bib9], [@bib10]\]. One report even observed α-Klotho to induce C/EBPα- and PPARγ gene expression, which promotes adipocyte differentiation in cultured 3T3-L1 adipocytes [@bib20]. While the source of discrepancy between the studies is not clear, it is evident that the nature of α-Klotho\'s role in regulation of adipogenesis and lipid metabolism is complex. Additional research is still needed and the signaling mechanisms responsible for α-Klotho-mediated changes in lipid-related gene expression remain unknown.

Overall the current study indicates improved energy expenditure and reduced adiposity in α-Klotho-treated DIO mice. This encouraging therapeutic potential is supported by past literature observing beta cell specific α-Klotho overexpression to attenuate the progression of diabetes via improved insulin release and ROS buffering \[[@bib6], [@bib16], [@bib21]\]. Furthermore, in α-Klotho deficient mice, non-shivering thermogenesis and gene expression of uncoupling protein 1 are impaired, while gluconeogenic gene expression in the liver is elevated [@bib10]. However, the role of α-Klotho in the pathophysiology of metabolic disease is complex. α-Klotho overexpressing mice live longer, but experience insulin resistance [@bib9]. Interestingly, these mice do not experience hyperglycemia, adiposity, or hyperphagia associated with clinical insulin resistance [@bib9]. Conversely, mice with impaired α-Klotho gene expression have increased insulin sensitivity, but experience many disease phenotypes associated with accelerated aging \[[@bib10], [@bib17]\]. These convoluted results may be explained by α-Klotho acting as a homeostatic modulator of insulin and IGF-1 signaling to prevent hypoglycemia, and enhance FOXO activity to reduce apoptosis and improve ROS buffering \[[@bib9], [@bib22], [@bib23]\].

Currently, the major gap in knowledge regarding α-Klotho\'s functions continues to be uncertainty surrounding the direct targets of α-Klotho. For example, the receptor for α-Klotho has yet to be discovered. Emerging evidence suggests that α-Klotho forms constitutive scaffolding complexes with fibroblast growth factor receptors (FGFR\'s) 1c, 3c, and 4 to increase the affinity of these FGFRs to fibroblast growth factor (FGF23) [@bib24]. Since FGFRs are ubiquitous, but α-Klotho expression is tissue-specific, it seems α-Klotho\'s presence governs whether a cell is an FGF23 target. Furthermore, FGFR\'s affinity to FGF23 in the absence of α-Klotho is very low, indicating α-Klotho may be required to activate FGFRs and their downstream signaling molecules [@bib11]. It is possible that the α-Klotho-FGFR complex and subsequent signaling pathways may be responsible for α-Klotho\'s roles regulating energy metabolism. This hypothesis is supported by the previously described FGF21-FGFR signaling mechanisms that result in elevated energy expenditure, improved insulin signaling, and reversed hepatic steatosis in DIO mice \[[@bib25], [@bib26]\]. Specifically, deletion of FGFR1c in adipose tissue abolished the therapeutic ability of FGFs to lower plasma glucose, increase insulin and triglycerides, and alter serum levels of adipokines [@bib26]. Furthermore, dominant-negative fibroblast growth factor receptor (FGFR) expression in hepatocytes of transgenic mice resulted in a fatty liver phenotype [@bib27]. Taken together these studies suggest FGFR signaling in adipose tissue and liver is important to homeostatic regulation of fat metabolism. Future studies should investigate the hypothesis that α-Klotho may result in activation of FGFR1 and its downstream signaling pathway, leading to transcriptional changes related to lipid metabolism and reduced adiposity.

Among many signaling pathways activated by FGFRs, PI3Kinase (PI3K) signaling is involved in homeostatic regulation of energy metabolism \[[@bib28], [@bib29], [@bib30], [@bib31]\]. Activated PI3K signaling phosphorylates forkhead box proteins, FOXO1, FOXO3a, and FOXO4, preventing translocation into the nucleus, and resulting in a loss of their transcriptional activity [@bib32]. One report suggests that FOXO1 positively regulates adipogenesis through its binding to the promoter region of PPARγ [@bib33]. Therefore, FGFR-mediated PI3kinase signaling, and subsequent FOXO1 inhibition, could be a possible mechanism explaining reduced adiposity via decreased PPARγ activity.

Although α-Klotho is theoretically not permeable to the blood brain barrier (BBB) due to its molecular size [@bib34], there is a recent study reporting that α-Klotho-F, a fragment of the α-Klotho protein described in this study, can acutely improve cognitive and motor functions following peripheral administration in young, aging, and hSYN transgenic mice [@bib35]. One must consider that some of the lipid reducing effects by α-Klotho may also be associated with the central nervous system (CNS). However, how peripheral α-Klotho transmits a signal to the CNS remains to be answered. Possibilities include modification of other circulating factors that can cross the BBB or alteration of central α-Klotho levels, either directly or indirectly. Our study does not rule out that α-Klotho might also act with the CNS but, rather, poses the question of the possibility of such a phenomenon.

In conclusion, our study demonstrates that 5-weeks administration of α-Klotho improves adiposity in DIO mice, mainly via lowering the lipid accumulation in liver and adipose tissue. The observed shift in lipid metabolism favoring oxidation rather than storage in liver and adipose begins to shed light on the tissue specific mechanisms responsible for α-Klotho\'s role in energy metabolism. The encouraging therapeutic potential of α-Klotho shown in the current study highlights a need for further research into this phenomenon, including investigations into likely α-Klotho induced FGFR1 signaling in liver and adipose tissue.
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